# Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation

> **NCT00383994** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Lymphoma
- Leukemia
- Transplantation, Stem Cell
- Lymphoid Malignancies
- Disorder Related to Transplantation

## Interventions

- **DRUG:** GM-CSF
- **DRUG:** Rituximab
- **BIOLOGICAL:** NK Cell Infusion

## Key facts

- **NCT ID:** NCT00383994
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2019-07-22
- **Final completion:** 2019-07-22
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00383994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00383994, "Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00383994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*